



## A Modern Take on Replicating Viral Vaccines

Guest Editors:

**Dr. Markus Kainulainen**

Viral Special Pathogens Branch,  
Centers for Disease Control and  
Prevention (CDC), Atlanta, GA  
30329, USA

**Dr. Anthony Griffiths**

National Infectious Diseases  
Laboratories, Boston University,  
Boston, MA, USA

### Message from the Guest Editors

Arguably the greatest accomplishments in curtailing viral diseases have been made possible by live-attenuated vaccines. Modern molecular techniques and research into virology, immunology, and pathogenesis enable the design of safe and potent novel candidates, yet the live-attenuated approach seems to have gone out of fashion. Is there still a place for attenuated vaccines, or have other approaches, like mRNA, made them obsolete?

Deadline for manuscript  
submissions:  
**closed (31 December 2022)**

This Special Issue welcomes articles that probe various topics around live-attenuated vaccine candidates against important viral diseases. We welcome rational attenuation strategies, characterization of natural strain variation, efficacy and safety results in animal models and the clinic, studies of genetic stability, immunological correlates of protection, and comparative pathology. Additionally, we are interested in reports on reversion, shedding, or other topics with safety implications.

Let us make this Special Issue a thought-provoking forum on the possibilities and special considerations of this approach!





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)